Survey: Doctors Want FDA To Reverse Course on Biosimilar Naming
November 17, 2016
Prescribers prefer the use of meaningful suffixes to identify biosimilars, as opposed to the random four-letter naming framework FDA is currently pursuing, according to a new survey published by the Biologics Prescribers Collaborative. The new biosimilar user fee agreement commits FDA to finalizing its controversial guidance on biosimilar naming by 2019. Industry and disease advocates have pushed the agency since the publishing of the draft guidance in 2015 to reverse course on naming. “According to a SERMO poll representing physicians...
Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting as the incoming Trump administration takes aim at the Affordable Care Act.